NCT06649266View on ClinicalTrials.gov

Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 21, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

Chronic Hepatitis D

Interventions

DRUG

RBD1016

RBD1016, active drug.

DRUG

Placebo

Placebo that is identical in appearance and volume to the doses of active IMP.

Trial Locations (2)

14186

Medicinsk enhet för Infektionssjukdomar, Karolinska Universitetssjukhuset Huddinge, Stockholm

18288

Infektionskliniken, Danderyds sjukhus, Stockholm

All Listed Sponsors

lead

Ribocure Pharmaceuticals AB

INDUSTRY

NCT06649266 - Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D | Biotech Hunter | Biotech Hunter